One Stop Solution For In-Depth Market Research Reports

詳細な市場調査レポートのワンストップソリューション

Home    >    HEALTHCARE AND PHARMACEUTICALS   >   Mild Traumatic Brain Injury Treatment Market

[ 英語タイトル ] Mild Traumatic Brain Injury Treatment Market - Growth, Trends, and Forecasts (2020 - 2025)


Product Code : MDHC0084158
Survey : Mordor Intelligence
Publish On : November, 2020
Number of Pages : 112
Category : Healthcare and Pharmaceuticals
Study Area : Global
Report format : PDF
Sales price option (consumption tax not included)
Single User USD4250 / Question Form
5 User USD4750 / Question Form
Enterprise User USD7500 / Question Form
 - Grace Laboratories LLC.
- Integra LifeSciences Corporation
- Medtronic PLC
- Neuren Pharmaceuticals Ltd.
- NeuroVive Pharmaceutical AB
- Stemedica Cell Technologies Inc.
- TEVA Pharmaceutical Industries Ltd.
- Vasopharm GmbH

[Report Description]

The Mild Traumatic Brain Injury Treatment market is expected to witness a CAGR of 3.8% during the forecast period. Certain factors that are driving the market growth include increasing incidence of mild traumatic brain injuries, and ongoing product development and approval.

Mild traumatic brain injury (MTBI) is a frequent medical condition, and some patients report long-lasting problems after MTBI. In order to prevent MTBI, knowledge of epidemiology is an important, and potential bias in studies should be explored. Traumatic brain injury (TBI) is a complex injury comprising a spectrum from mild TBI (MTBI) with low risk of persistent disability, to the most severe TBI with devastating brain damage. However, MTBI constitutes 80–90 % of all TBI. Therefore the rising incidences and injuries being caused to the brain worldwide resulting in a high prevalence of target disorders are expected to impact the market in a positive manner.

Key Market Trends

Hospital is Expected to Hold Significant Market Share in the End User Segment

The therapy for mild traumatic brain injury treatment usually begins in the hospital and continues at an inpatient rehabilitation unit, a residential treatment facility, or through outpatient services. The type and duration of rehabilitation are different for everyone, depending on the severity of the brain injury and what part of the brain was injured. People with mild traumatic brain injuries may also have other injuries that need to be addressed.

Additional treatments in the emergency room or intensive care unit of a hospital generally focus on minimizing secondary damage due to inflammation, bleeding, or reduced oxygen supply to the brain.

North America Dominates the Market and Expected to do Same in the Forecast Period

Traumatic brain injury (TBI), also known as acquired brain injury, head injury, or brain injury, causes substantial disability and mortality in the American population. It occurs when a sudden trauma damages the brain and disrupts normal brain function. TBI often has profound physical, psychological, cognitive, emotional, and social effects on the lives of American people. Mild TBI appears to be vastly under-diagnosed in the setting of systemic trauma, even in trauma centers. According to the CDC, there were approximately 2.8 million TBI-related emergency department visits, hospitalizations, and deaths in the United States in 2015. Hence, the rising prevalence of MTBI is expected to drive the overall growth of the market across the entire region.

Competitive Landscape

The global Mild Traumatic Brain Injury Treatment market is highly competitive and consists of a number of major players. Companies like Grace Laboratories LLC., Integra LifeSciences Corporation, Medtronic PLC, Neuren Pharmaceuticals Ltd., NeuroVive Pharmaceutical AB , Stemedica Cell Technologies Inc., TEVA Pharmaceutical Industries Ltd., Vasopharm GmbH, among others, hold the substantial market share in the Mild Traumatic Brain Injury Treatment market.

Reasons to Purchase this report:

- The market estimate (ME) sheet in Excel format
- 3 months of analyst support

1 INTRODUCTION
1.1 Study Deliverables
1.2 Study Assumptions
1.3 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Increasing Incidence Of Mild Traumatic Brain Injuries
4.2.2 Ongoing Product Development And Approval
4.3 Market Restraints
4.3.1 Stringent Regulatory Framework
4.3.2 Shortage Of Trained Professionals
4.4 Porter's Five Force Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry

5 MARKET SEGMENTATION
5.1 By Treatment
5.1.1 Drugs
5.1.2 Surgery
5.2 End Users
5.2.1 Hospitals
5.2.2 Clinics
5.2.3 Others
5.3 Geography
5.3.1 North America
5.3.1.1 United States
5.3.1.2 Canada
5.3.1.3 Mexico
5.3.2 Europe
5.3.2.1 Germany
5.3.2.2 United Kingdom
5.3.2.3 France
5.3.2.4 Italy
5.3.2.5 Spain
5.3.2.6 Rest of Europe
5.3.3 Asia Pacific
5.3.3.1 China
5.3.3.2 Japan
5.3.3.3 India
5.3.3.4 Australia
5.3.3.5 South korea
5.3.3.6 Rest of Asia-Pacific
5.3.4 Middle East and Africa
5.3.4.1 GCC
5.3.4.2 South Africa
5.3.4.3 Rest of Middle East and Africa
5.3.5 South America
5.3.5.1 Brazil
5.3.5.2 Argentina
5.3.5.3 Rest of South America

6 COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.1 Grace Laboratories LLC.
6.1.2 Integra LifeSciences Corporation
6.1.3 Medtronic PLC
6.1.4 Neuren Pharmaceuticals Ltd.
6.1.5 NeuroVive Pharmaceutical AB
6.1.6 Stemedica Cell Technologies Inc.
6.1.7 TEVA Pharmaceutical Industries Ltd.
6.1.8 Vasopharm GmbH

7 MARKET OPPORTUNITIES AND FUTURE TRENDS

渋谷データカウント

渋谷データカウントは、最も信頼性が高く最新の調査分析レポートを確実に提供する経験豊富な調査専門家のグローバルチームが提供する、さまざまな業界のさまざまな市場調査レポートを提供する再販代理店です。

Recommended reports

+